Safety Evaluation of Contezolid (MRX-I) Versus Linezolid in Sprague-Dawley Rats
Abstract Background & Objectives Contezolid (MRX-I) is a novel ortho-fluorophenyl dihydropyridone developed by MicuRx Pharmaceuticals, Inc. It has been approved for the treatment of drug-resistant Gram-positive bacterial infections with relatively lower toxicity than other oxazolidinones such as lin...
Uloženo v:
| Hlavní autoři: | , , , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Adis, Springer Healthcare
2025-05-01
|
| Edice: | Drugs in R&D |
| On-line přístup: | https://doi.org/10.1007/s40268-025-00504-x |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|